SCHEDULE: Bicycle Therapeutics: Invus Group Discloses Stake

Invus Group entities and related parties have reported beneficial ownership of 3.1% of Bicycle Therapeutics plc's ordinary shares as of March 31, 2026.

Summary

• Several entities associated with Invus Group, including Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Mr. Raymond Debbane, have filed a Schedule 13G.
• As of March 31, 2026, these reporting persons collectively hold 1,560,882 American Depositary Shares (ADSs) of Bicycle Therapeutics plc.
• This represents a beneficial ownership of 3.1% of the company's outstanding ordinary shares.
• Invus Public Equities directly holds 1,368,586 ADSs, and Avicenna Life Sci Master Fund LP directly holds 192,296 ADSs.
• The filing indicates that the reporting persons do not hold these shares for the purpose of influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership and does not contain operational or financial performance updates.

Positives

• Significant investment by Invus Group entities, indicating confidence in Bicycle Therapeutics' long-term prospects.
• Clear disclosure of beneficial ownership, adhering to regulatory requirements.
• The filing explicitly states that the shares are not held for the purpose of changing or influencing control, suggesting a passive investment strategy.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that significant stake acquisitions or increases in beneficial ownership by institutional investors, as reported in Schedule 13G filings, can signal investor conviction and potentially influence market perception of a company's valuation and future prospects within the biotechnology sector.

Stakeholder Impact

• Shareholders: Increased institutional interest may be viewed positively, potentially indicating confidence in the company's strategy.
• Management: The disclosure confirms a significant passive investment, which typically does not directly impact day-to-day operations unless the investor decides to become more active.

Key Dates

Keywords

Bicycle Therapeutics, Schedule 13G, Invus Group, Beneficial Ownership, American Depositary Shares, Ordinary Shares, SEC Filing, Investment, Raymond Debbane